Codiak BioSciences’ $76.5 Million Series C Financing

Goodwin advised Codiak BioSciences on the deal

Codiak BioSciences, Inc., the leading exosome therapeutics company, today announced the closing of a Series C financing round of $76.5 million. In its two years as a company Codiak’s funding totals $168.5 million. Codiak’s initial investors, including ARCH Venture Partners, Flagship Pioneering, Fidelity Management and Research Company, the Alaska Permanent Fund, and Alexandria Venture Investments, participated in the Series C round, and were joined by new investors, including Qatar Investment Authority, Boxer Capital of the Tavistock Group, Sirona Capital, EcoR1 Capital, and Casdin Capital.

Codiak intends to use the proceeds of the Series C financing to advance its initial product candidates into clinical trials, and to continue to develop the company’s transformational exosome therapeutic platform.

Codiak, founded in 2015, is the leader in the rapidly developing field of exosome therapeutics. The company was formed on the basis of research from the VentureLabs innovation unit of Flagship Pioneering; the research of Jan Lotvall, M.D., Ph.D., Chairman of the Krefting Research Centre at University of Gothenburg, Sweden; and Raghu Kalluri, M.D., Ph.D., at The University of Texas MD Anderson Cancer Center in Houston, Texas.

The Goodwin team was led by partner Stephen Davis (Picture) and included partner Daniel Lang; associates Andrew Pusar, Charles Lu and Zain Ahmad; and senior paralegal Bryan Snyder.

Involved fees earner: Stephen Davis – Goodwin Procter; Daniel Lang – Goodwin Procter; Andrew Pusar – Goodwin Procter;

Law Firms: Goodwin Procter;

Clients: Codiak Biosciences, Inc.;


Author: Ambrogio Visconti